Short Summary
ENS Labs Ltd. has filed a Petition for Inter Partes Review challenging Unstoppable Domains Inc.'s patent covering Domain Name Resolution (ENS) methods. The petitioner argues that the core claims are obvious under 35 U.S.C. § 103 by combining multiple prior art references related to blockchain functionality.
Detailed Summary
This Petition challenges twenty claims of Patent 11558344, asserting that the technology for ENS resolution is rendered obvious. The petitioner's central theory relies on combining foundational documents like Johnson and Millegan with various technical standards (EIP-137) and patents (Schneider, Haynes, Saini). These combinations are argued to predictably lead to methods of resolving an ENS name into a website address via the Ethereum blockchain.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in ENS Labs Ltd. vs Unstoppable Domains Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Apple Inc.vsApex Beam Technologies LLC
Apple has filed a petition for inter‑partes review of Apex Beam’s U.S. Patent 10,568,113 covering LTE beam‑failure recovery. The petition asserts that the claims are obvious over Xia, Jover, 3GPP‑LTE and Yi references under §103 and requests institution of the IPR.
Samsung Display Co., Ltd. et al.vsPictiva Displays International Ltd.
Samsung Display’s IPR petition challenging Pictiva’s display patent was denied after the Director affirmed the Board’s discretionary denial of institution, leaving the patent intact.
Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.
Halozyme seeks Director Review to overturn the PTAB’s institution of a post‑grant review against its hyaluronidase patent, arguing filing‑date errors, improper claim construction, and Fintiv factors favoring denial.
Medela LLC et al.vsM.E.A.C. Engineering Ltd.
Medela and M.E.A.C. Engineering settled their IPR dispute over patent 8,858,534 B2. The Board terminated the proceeding before any trial, keeping the settlement confidential.
Abbott Diabetes Care Inc. et al.vsDexCom, Inc.
Abbott Diabetes Care and DexCom settled their dispute over U.S. Patent 11,020,031 B1. The PTAB granted a joint motion to terminate the IPR and ordered the settlement agreement to be kept confidential.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.